Key result
Older age linked to ~9% lower odds of oral anticoagulant prescription in octogenarians with AF.
Why the study?
Managing anticoagulation in very elderly patients aged ≥ 80 years with AF is challenging, and real-world data on oral anticoagulant use and associated factors in this population are limited.
Observational (n=432)
In real-world practice, nearly 40% of patients aged ≥80 years with atrial fibrillation do not receive oral anticoagulation, driven by advanced age, lower functional status, prior gastrointestinal bleeding, and concomitant antiplatelet therapy.
Answers are grounded in this paper and cite their sources.
Highlights variability in anticoagulant use among octogenarians with AF; leaves open optimal strategies pending prospective trials.
Background Atrial fibrillation (AF) substantially increases the risk of stroke; however, anticoagulation therapy can reduce the risk of AF-related stroke and death. Managing anticoagulation in very elderly patients (≥ 80 years) with AF is particularly challenging, and real-world data on its use in this population are limited. This study aimed to assess the prevalence of non-use of oral anticoagulants (OAC) and identify associated factors in very elderly patients. Methods This retrospective study included patients aged ≥ 80 years with AF who were consecutively discharged between July 2021 and July 2024. Patients were classified according to oral anticoagulant (OAC) use into OAC and non-OAC groups. Subgroup analyses compared patients receiving OAC alone with those receiving OAC plus antiplatelet therapy (APT), and patients receiving APT alone with those receiving no antithrombotic therapy. Multivariable analysis was performed to identify factors associated with anticoagulation use. Results The study included 432 patients with a median age of 84 years; 48.1% were male. The median CHA2DS2-VA score was 5 points. Overall, 61.8% of eligible patients received OACs. Among OAC users, 4.1% received warfarin and 95.9% received direct oral anticoagulant (DOAC). In the full cohort, 53.7% received OAC alone, 8.1% received OAC plus APT, 15.3% received APT alone, and 22.9% received no antithrombotic therapy. In the multivariable model, In the multivariable model, a higher ADL score (adjusted odds ratio [aOR] = 1.021; 95% confidence interval [CI], 1.009–1.033), a higher CHA 2 DS 2 -VA score (aOR = 1.332; 95% CI, 1.138–1.559) was associated with higher odds of OAC use. Older age (aOR = 0.909; 95% CI, 0.853–0.968), a history of gastrointestinal bleeding (aOR = 0.252; 95% CI, 0.103–0.618), and concomitant antiplatelet use (aOR = 0.150; 95% CI, 0.086–0.263) were associated with lower odds of OAC use. Among patients receiving OACs, coronary artery disease (CAD; aOR = 6.662; 95% CI, 2.379–22.880) were associated with higher odds of receiving OAC plus APT rather than OAC alone. Among patients not receiving OACs, CAD was associated with higher odds of APT use (aOR = 6.562; 95% CI, 2.745–15.686), whereas cancer was associated with lower odds of APT use (aOR = 0.161; 95% CI, 0.049–0.525), with no antithrombotic therapy as the reference category. Older age (aOR = 1.086; 95% CI, 1.000-1.185), longer length of stay (aOR = 1.085; 95% CI, 1.028–1.152), higher eGFR (aOR = 1.011; 95% CI, 1.001–1.021) were associated with higher odds of DOAC inappropriate prescriptions. Conclusions Non-use of OAC was common among very elderly patients. Older age, lower ADL scores, a history of gastrointestinal bleeding, and concomitant antiplatelet use were associated with a lower likelihood of receiving anticoagulation. Older age, longer length of stay, and higher eGFR was correlated with an increased likelihood of inappropriate DOAC prescriptions.
No takes yet. Share an insight, caveat, or question.
Bai et al. (2026) conducted an observational in Atrial fibrillation (n=432). Oral anticoagulant (OAC) use and associated clinical factors vs. Non-use of oral anticoagulants (Non-OAC) was evaluated on Prevalence of oral anticoagulant (OAC) use and associated factors (OR 0.909, 95% CI 0.853-0.968). Oral anticoagulants were prescribed to 61.8% of AF patients aged ≥80 years, with older age and GI bleeding reducing odds of use.
Synapse has enriched 10 related papers. Consider them for comparative context: